Abbott India to distribute Novo Nordisk's semaglutide drug brand in India
This story was originally published at 16:25 IST on 27 February 2026
Register to read our real-time news.Informist, Friday, Feb. 27, 2026
--Abbott India, Novo Nordisk partner to commercialise Extensior semaglutide
MUMBAI – Abbott India Ltd. will distribute Novo Nordisk's semaglutide drug brand Extensior, which is a second brand of Ozempic, the company said in an exchange filing Friday. The drug is used to treat type 2 diabetes and also helps with weight loss and reduce risk of heart disease.
"This partnership leverages Novo Nordisk's scientific leadership in GLP-1s and Abbott's strong distribution network to expand access in India to a high-quality, evidence-based diabetes therapy, beyond regions Novo Nordisk currently serves," the company said.
For the quarter ended December, Abbott India reported a net profit of INR 3.76 billion on a revenue of INR 17.24 billion. Friday, its shares closed at INR 26,530 on the National Stock Exchange, down 0.7% from Thursday. End
Reported by Anshul Choudhary
Edited by Saji George Titus
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
